

ACCURATUS
LAB SERVICES

PROTOCOL

**Virucidal Efficacy of a Disinfectant for Use on
Inanimate Environmental Surfaces**

Virus: Infectious Laryngotracheitis virus

PROTOCOL NUMBER

VIR07052716.ILGT

PREPARED FOR/SPONSOR

Virox Technologies Inc.
2770 Coventry Road
Oakville, ON L6H 6R1
Canada

PREPARED BY/TESTING FACILITY

Accuratus Lab Services
1285 Corporate Center Drive, Suite 110
Eagan, MN 55121

DATE

May 27, 2016

EXACT COPY
INITIALS *h* DATE 9/9/16

PROPRIETARY INFORMATION

THIS DOCUMENT IS THE PROPERTY OF AND CONTAINS PROPRIETARY INFORMATION OF ACCURATUS LAB SERVICES. NEITHER THIS DOCUMENT, NOR INFORMATION CONTAINED HEREIN IS TO BE REPRODUCED OR DISCLOSED TO OTHERS, IN WHOLE OR IN PART, NOR USED FOR ANY PURPOSE OTHER THAN THE PERFORMANCE OF THIS WORK ON BEHALF OF THE SPONSOR, WITHOUT PRIOR WRITTEN PERMISSION OF ACCURATUS LAB SERVICES.

Protocol Number: VIR07052716.ILGT

Virox Technologies Inc.
Page 2 of 12



Virucidal Efficacy of a Disinfectant for Use on Inanimate Environmental Surfaces

PURPOSE

The purpose of this study is to evaluate the virucidal efficacy of a test substance for registration of a product as a virucide. The test procedure is to simulate the way in which the product is intended to be used. This method is in compliance with the requirements of and may be submitted to, one or more of the following agencies as indicated by the Sponsor: U.S. Environmental Protection Agency (EPA), Health Canada and Australian Therapeutic Goods Administration (TGA).

TEST SUBSTANCE CHARACTERIZATION

According to 40 CFR, Part 160, Subpart F (160.105) test substance characterization as to identity, strength, purity, solubility and composition, as applicable, shall be documented before its use in this study. The stability of the test substance shall be determined prior to or concurrently with this study. Pertinent information, which may affect the outcome of this study, shall be communicated in writing to the Study Director upon sample submission to Accuratus Lab Services. Accuratus Lab Services will append Sponsor-provided Certificates of Analysis (C of A) to this study report, if requested and supplied. Characterization and stability studies not performed following GLP regulations will be noted in the Good Laboratory Practice compliance statement.

SCHEDULING AND DISCLAIMER OF WARRANTY

Experimental start dates are generally scheduled on a first-come/first-serve basis once Accuratus Lab Services receives the Sponsor approved/completed protocol, signed fee schedule and corresponding test substance(s). Based on all required materials being received at this time, the proposed experimental start date is June 20, 2016. Verbal results may be given upon completion of the study with a written report to follow on the proposed completion date of July 18, 2016. To expedite scheduling, please be sure all required paperwork and test substance documentation is complete/accurate upon arrival at Accuratus Lab Services.

If a test must be repeated, or a portion of it, because of failure by Accuratus Lab Services to adhere to specified procedures, it will be repeated free of charge. If a test must be repeated, or a portion of it, due to failure of internal controls, it will be repeated free of charge. "Methods Development" fees shall be assessed, however, if the test substance and/or test system require modifications due to complexity and difficulty of testing.

If the Sponsor requests a repeat test, they will be charged for an additional test.

Neither the name of Accuratus Lab Services nor any of its employees are to be used in advertising or other promotion without written consent from Accuratus Lab Services.

The Sponsor is responsible for any rejection of the final report by the regulatory agency of its submission concerning report format, pagination, etc. To prevent rejection, Sponsor should carefully review the Accuratus Lab Services final report and notify Accuratus Lab Services of any perceived deficiencies in these areas before submission of the report to the regulatory agency. Accuratus Lab Services will make reasonable changes deemed necessary by the Sponsor, without altering the technical data.


JUSTIFICATION FOR SELECTION OF THE TEST SYSTEM

Regulatory agencies require that a specific virucidal claim for a disinfectant intended for use on hard surfaces be supported by appropriate scientific data demonstrating the efficacy of the test substance against the claimed virus. Each agency will accept adequate data generated by any appropriate technique in support of a virucidal efficacy claim. This is accomplished by treating the target virus with the disinfectant (test substance) under conditions, which simulate as closely as possible, in the laboratory, the actual conditions under which the disinfectant is designed to be used. For disinfectant products intended for use on hard surfaces (dry, inanimate environmental surfaces), a carrier method is used in the generation of the supporting virological data. The CEK cell line, which supports the growth of the Infectious Laryngotracheitis virus, will be used in this study. The experimental design in this protocol meets these requirements.

Template: 110-1J

— Proprietary Information —

1285 Corporate Center Drive, Suite 110 • Eden, MN 55121 • 877.287.8378 • 651.378.5510 • www.accuratuslabs.com



TEST PRINCIPLE

A film of virus, dried on a glass surface, is exposed to the test substance for a specified exposure time. At the end of the exposure time, the virucidal and cytotoxic activities are removed from the virus-test substance mixture, and the mixture is assayed for viral infectivity by an accepted assay method. Appropriate virus, test substance cytotoxicity, and neutralization controls are run concurrently.

STUDY DESIGN

Dried virus films will be prepared in parallel and used as follows:

The appropriate number of films for each batch of test substance assayed per exposure time requested.

The appropriate number of films for virus control titration (titer of virus after drying) per exposure time requested.

The inoculated carriers are exposed to the test substance for the Sponsor specified exposure time. At the end of the specified exposure time, resuspended virus-test substance mixtures will be detoxified and made non-virucidal by immediately adding the contents to a Sephadex gel filtration column followed by 10-fold serial dilutions in test medium. Each dilution is inoculated into indicator cell cultures. The resuspended virus control film and each batch of test substance alone will be treated in exactly the same manner. For analysis of infectivity, cultures will be held for the appropriate incubation period at the end of which time cultures will be scored for the presence of the test virus. Cultures will be monitored at that time for cell viability. Uninfected indicator cell cultures will be carried in parallel and similarly monitored. For analysis of cytotoxicity, the viability of cultures inoculated with dilutions of each test and cytotoxicity control will be determined. In addition to the above titrations for infectivity and cytotoxicity, the residual virucidal activity of the test substance after neutralization will be determined by adding a low titer of stock virus to each dilution of the test substance (cytotoxicity control dilutions). The resulting mixtures of dilutions are assayed for infectivity in order to determine the dilution(s) of test substance at which virucidal activity, if any, is retained.


VIRUS

The LT-IVAX (Modified live vaccine) strain of Infectious Laryngotracheitis virus to be used for this study was obtained from Poultry Health and Specities, St. Cloud, MN. Stock virus is prepared by collecting the supernatant culture fluid from 75-100% infected culture cells. The cells are disrupted and cell debris removed by centrifugation. The supernatant is removed, aliquoted, and the high titer stock virus may be stored at $\leq -70^{\circ}\text{C}$ until the day of use. Alternate methods of viral propagation may be utilized based on the growth requirements of the virus. The propagation method will be specified in the raw data and in the report. On the day of use the appropriate number of aliquots are removed, thawed, combined (if applicable) and maintained at a refrigerated temperature until used in the assay. Note: If the Sponsor requests an organic soil load challenge, fetal bovine serum (FBS) or the requested organic soil will be incorporated into the stock virus aliquot. The stock virus aliquot will be adjusted to yield the percent organic soil load requested.

INDICATOR CELL CULTURES

Cultures of chicken embryo kidney (CEK) cells were originally obtained from Charles River. The cells are propagated by Accuratus Lab Services personnel. The cells are seeded into multiwell cell culture plates and maintained at 36-38°C in a humidified atmosphere of 5-7% CO₂. The confluency of the cells will be appropriate for the test virus. CEK cells obtained from an alternate, reputable source may be used. The source of the cells will be specified in the final report.

All cell culture documentation is retained for the cell cultures used in this assay with respect to source, passage number, growth characteristics, seeding densities and the general condition of the cells.



TEST MEDIUM

The test medium used for this assay is Minimum Essential Medium (MEM) supplemented with heat inactivated lamb serum, 2.5 µm amphotericin B, 2.0 mM L-glutamine and 5% tryptose phosphate broth. The medium may also be supplemented with one or more of the following: 10 µg/mL gentamicin, 100 units/mL penicillin, 2.5 µg/mL amphotericin B, 1.0-2.0 mM L-glutamine, and 0.5 – 5 µg/mL trypsin. The composition of the test medium may be altered based on the virus and/or cells. The composition of the medium will be specified in the raw data and in the report.

PREPARATION OF TEST SUBSTANCE

The dilution of test substance(s) will be used as recommended by the Sponsor. The product will be pre-equilibrated to the desired test temperature if applicable.

PREPARATION OF VIRUS FILMS

Films of virus will be prepared by spreading 200 µL of virus inoculum uniformly over the bottom of the appropriate number of 100 X 15 mm sterile glass petri dishes (without touching the sides of the petri dish). The virus will be air-dried at 10°C-30°C until visibly dry (≥20 minutes). A calibrated timer will be used for timing the drying. The drying conditions (temperature and humidity) will be appropriate for the test virus for the purpose of obtaining maximum survival following drying. The actual drying conditions, drying time and calibrated timer used will be clearly documented.

One dried virus film per batch of test substance will be assayed unless otherwise requested.

TEST METHOD

Preparation of Sephadex Gel Filtration Columns


To reduce the cytotoxic level of the virus-test substance mixture prior to assay of virus, and/or to reduce the virucidal level of the test substance, virus is separated from the test substance by filtration through Sephadex gel. The type of Sephadex used will be specified in the final report. On the day of testing, Sephadex columns are prepared by centrifuging the prepared Sephadex gel in sterile syringes for three minutes to clear the void volume. The columns are now ready to be used in the assay.

Input Virus Control

On the day of testing, the stock virus utilized in the assay will be titrated by 10-fold serial dilution and assayed for infectivity to determine the starting titer of the virus. The results of this control are for informational purposes only.

Treatment of Virus Films with the Test Substance

For each batch of test substance assayed, the appropriate number of dried virus films are individually exposed to a 2.0 mL aliquot of the use dilution of the test substance (liquid products), or to the amount of spray released under use conditions (spray products) and held covered for the specified exposure time(s) and temperature. A calibrated timer will be used for timing the exposure. The actual temperature will be recorded. Just prior to the end of the exposure time, the plates are individually scraped with a cell scraper to resuspend the contents and at the end of the exposure time the virus-test substance mixtures are immediately passed through individual Sephadex columns utilizing the syringe plunger in order to detoxify the mixture. The filtrate (10⁻¹ dilution) is then filtered by serial dilution and assayed for infectivity and/or cytotoxicity. To further aid in the removing of the cytotoxic effects of the test substance to the indicator cell cultures, individual dilutions may be passed through additional individual Sephadex columns.



Protocol Number: VIR07052716.ILGT

Virox Technologies Inc.
Page 5 of 12



ACCURATUS
LAB SERVICES

Treatment of Dried Virus Control Film

The appropriate number of virus films are prepared as described previously for each exposure time assayed. The virus control films are run in parallel to the test virus but a 2.0 mL aliquot of test medium is added in lieu of the test substance. The virus control films are held covered and exposed to the test medium for the same exposure time and at the same exposure temperature as the test films are exposed to the test substance. A calibrated timer will be used for timing the exposure and the actual temperature will be recorded. Just prior to the end of the exposure time, the virus films are individually scraped as previously described and at the end of the exposure time the mixtures are immediately passed through individual Sephadex columns utilizing the syringe plunger. The filtrate (10^{-1} dilution) is then titrated by serial dilution and assayed for infectivity. If additional Sephadex columns were used to further reduce the cytotoxic effects in the test substance assay, the same dilutions of the virus control will be passed through additional individual Sephadex columns.

Cytotoxicity Control

A 2.0 mL aliquot of each batch of test substance (liquid products) or the amount of the test substance recovered when sprayed onto a sterile petri dish (spray products), is filtered through a Sephadex column utilizing the syringe plunger and the filtrate is diluted serially in medium and inoculated into cell cultures for assay of cytotoxicity concurrently with the virus control and test substance-treated virus samples. For spray products, the cytotoxicity control will be held covered for the longest requested exposure time at the requested exposure temperature. A calibrated timer will be used for timing the exposure. If additional Sephadex columns were used to further reduce the cytotoxic effects in the test substance assay, the same dilutions of the cytotoxicity control will be passed through additional individual Sephadex columns.

Assay of Non-Virucidal Level of Test Substance (Neutralization Control)

Each dilution of the neutralized test substance (cytotoxicity control dilutions) will be challenged with an aliquot of low titer stock virus to determine the dilution(s) of test substance at which virucidal activity, if any, is retained. Dilutions that show virucidal activity will not be considered in determining reduction of the virus by the test substance.

Using the cytotoxicity control dilutions prepared above, an additional set of indicator cell cultures will be inoculated with a 100 μ L aliquot of each dilution in quadruplicate. A 100 μ L aliquot of low titer stock virus will be inoculated into each cell culture well and the indicator cell cultures will be incubated along with the test and virus control plates.

Infectivity Assays

The CEK cell line, which exhibits cytopathic effect (CPE) in the presence of infectious Laryngotracheitis virus, will be used as the indicator cell line in the infectivity assays. Cells in multiwell culture dishes will be inoculated in quadruplicate with 100 μ L of the dilutions prepared from test and control groups. The input virus control will be inoculated in duplicate. Uninfected indicator cell cultures (cell controls) will be inoculated with test medium alone. The cultures are incubated at 36-38°C in a humidified atmosphere of 5-7% CO₂ in sterile disposable cell culture labware for approximately seven days. Periodically throughout the incubation time the cultures will be microscopically observed for the absence or presence of CPE, cytotoxicity and for viability. The observations will be recorded on the raw data worksheets; only the results from the final observations will be reported.

DATA ANALYSIS

Calculation of Titers

Viral and cytotoxicity titers will be expressed as $-\log_{10}$ of the 50 percent titration endpoint for infectivity (TCID₅₀) or cytotoxicity (TCD₅₀), respectively, as calculated by the method of Spearman Karber.

$$-\text{Log of 1st dilution inoculated} - \left[\left(\left(\frac{\text{Sum of \% mortality at each dilution}}{100} \right) - 0.5 \right) \times (\text{logarithm of dilution}) \right]$$

Calculation of Log Reduction

Dried Virus Control Log₁₀ TCID₅₀ - Test Substance Log₁₀ TCID₅₀ = Log Reduction

If multiple dried virus control replicates are performed, the average titer of the replicates will be calculated and the average titer will be used to calculate the log reduction in viral titer of the individual test replicates.

Template: 110-1J

- Proprietary Information -

1285 Corporate Center Drive, Suite 110 • Eden, MN 55121 • 877.287.8378 • 851.379.5510 • www.accuratuslab.com



PROCEDURE FOR IDENTIFICATION OF THE TEST SYSTEM

The specialized virucidal testing section of Accuratus Lab Services maintains Standard Operating Procedures (SOPs) relative to virucidal efficacy testing studies. Virucidal efficacy testing is performed in strict adherence to these SOPs which have been constructed to cover all aspects of the work including, but not limited to, receipt, log-in, and tracking of biological reagents including virus and cell stocks for purposes of identification, receipt and use of chemical reagents including cell culture medium components, etc. These procedures are designed to document each step of virucidal efficacy testing studies. Appropriate references to medium, batch number, etc. are documented in the raw data collected during the course of each study.

Additionally, each virucidal efficacy test is assigned a unique Project Number when the Study Director initiates the protocol for the study. This number is used for identification of the test culture plates, etc. during the course of the test. Test culture plates are also labeled with reference to the test virus, experimental start date, and test product. These measures are designed to document the identity of the test system.

METHOD FOR CONTROL OF BIAS: N/A

STUDY ACCEPTANCE CRITERIA

Only the applicable acceptance criteria and references for the regulatory agency reviewing the data will be included in the final report.

U.S. EPA, Health Canada, and Australian TGA Submission

A valid test requires 1) that at least 4 log₁₀ of infectivity be recovered from the dried virus control film; 2) that when cytotoxicity is evident, at least a 3-log reduction in titer is demonstrated beyond the cytotoxic level; 3) that the cell controls be negative for infectivity. If any of the previous requirements are not met, the test may be repeated under the current protocol number. Note: An efficacious product must demonstrate complete inactivation of the virus at all dilutions.

If the test substance fails to meet the test acceptance criteria and the dried virus control fails to meet the control acceptance criteria, the study is considered valid and no repeat testing is necessary, unless requested by the Sponsor.


If any portion of the protocol is executed incorrectly warranting repeat testing, the test may be repeated under the current protocol number.

FINAL REPORT

The report will include, but not be limited to, identification of the sample and date received, dates on which the test was initiated and completed, identification of the virus strain used and composition of the inoculum, description of cells, medium and reagents, description of the methods employed, tabulated results, calculated titers for infectivity and cytotoxicity, and a conclusion as it relates to the purpose of the test. A draft report may be requested by the Sponsor. The final report will be prepared once the Sponsor has reviewed the draft report and notified the Study Director to complete the study.

PROTOCOL CHANGES

If it becomes necessary to make changes in the approved protocol, the revision and reasons for change will be documented, reported to the Sponsor and will become a part of the permanent file for that study. Similarly, the Sponsor will be notified as soon as possible whenever an event occurs that may have an effect on the validity of the study.



Protocol Number: VIR07052716.ILGT

Virox Technologies Inc.
Page 7 of 12



ACCURATUS
LAB SERVICES

TEST SUBSTANCE RETENTION

Test substance retention shall be the responsibility of the Sponsor. Unused test substance will be discarded following study completion unless otherwise requested.

RECORD RETENTION

Study Specific Documents

All of the original raw data developed exclusively for this study shall be archived at Accuratus Lab Services for a minimum of five years for GLP studies or a minimum of six months for all other studies following the study completion date. After this time, the Sponsor (or the Sponsor Representative, if applicable) will be contacted to determine the final disposition. These original data include, but are not limited to, the following:


1. All handwritten raw data for control and test substances including, but not limited to, notebooks, data forms and calculations.
2. Any protocol amendments/deviation notifications.
3. All measured data used in formulating the final report.
4. Memoranda, specifications, and other study specific correspondence relating to interpretation and evaluation of data, other than those documents contained in the final study report.
5. Original signed protocol.
6. Certified copy of the final study report.
7. Study-specific SOP deviations made during the study.

Facility Specific Documents

The following records shall also be archived at Accuratus Lab Services. These documents include, but are not limited to, the following:


1. SOPs which pertain to the study conducted.
2. Non study-specific SOP deviations made during the course of this study, which may effect the results obtained during this study.
3. Methods which were used or referenced in the study conducted.
4. QA reports for each QA inspection with comments.
5. Facility Records: Temperature Logs (ambient, incubator, etc.), Instrument Logs, Calibration and Maintenance Records.
6. Current curriculum vitae, training records, and job descriptions for all personnel involved in the study.

PROPOSED STATISTICAL METHODS: N/A



REFERENCES

1. Annual Book of ASTM Standards, Section 11 Water and Environmental Technology Volume 11.05 Pesticides, Antimicrobials, and Alternative Control Agents; Environmental Assessment; Hazardous Substances and Oil Spill Response, E1053-11.
2. Annual Book of ASTM Standards, Section 11 Water and Environmental Technology Volume 11.05 Pesticides, Antimicrobials, and Alternative Control Agents; Environmental Assessment; Hazardous Substances and Oil Spill Response, E1482-12.
3. U.S. Environmental Protection Agency, Office of Chemical Safety and Pollution Prevention, Product Performance Test Guidelines, OCSPP 810.2000: General Considerations for Uses of Antimicrobial Agents, September 4, 2012.
4. U.S. Environmental Protection Agency, Office of Chemical Safety and Pollution Prevention, Product Performance Test Guidelines, OCSPP 810.2200: Disinfectants for Use on Hard Surfaces – Efficacy Data Recommendations, September 4, 2012.
5. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. Lennette, E.H., Lennette, D.A. and Lennette, E.T. editors. Seventh edition, 1995.
6. Blackwell, J.H., and J.H.S. Chan. 1970. Effects of various germicidal chemicals on HEP-2 cell culture and Herpes simplex virus. J. AOAC 53:1229-1236.
7. Health Canada, January, 2014. Guidance Document - Disinfectant Drugs.
8. Health Canada, January, 2014. Guidance Document - Safety and Efficacy Requirements for Hard Surface Disinfectant Drugs.
9. Australian Therapeutic Goods Administration (TGA), February 1998. Guidelines for the Evaluation of Sterilants and Disinfectants.
10. Australian Therapeutic Goods Administration (TGA), February 1998. Therapeutic Goods Order No. 54: Standard for Disinfectants and Sterilants.
11. Australian Therapeutic Goods Administration (TGA), March 1997. Therapeutic Goods Order No. 54A: Amendment to Standard for Disinfectants and Sterilants (TGO 54).
12. Australian Therapeutic Goods Administration (TGA), July 2005. Draft Guidelines for the Evaluation of Household/Commercial and Hospital Grade Disinfectants.



Protocol Number: VIR07052716.ILGT

Virox Technologies Inc.

Page 9 of 12



ACCURATUS
LAB SERVICES

STUDY INFORMATION

(All blank sections are completed by the Sponsor or Sponsor Representative as linked to their signature, unless otherwise noted.)

Test Substance (Name and Batch Number - exactly as it should appear on final report):

Orbitem Lot# 12295, 12299

Testing at the lower certified limit (LCL) for the hardest-to-kill virus on your label is required for registration.

Product Description

- ☐ Quaternary ammonia
☐ Iodophor

- ☐ Paraformic acid
☐ Peroxide

- ☐ Sodium hypochlorite
☐ Other _____

Approximate Test Substance Active Concentration (upon submission to Accuratus Lab Services):

Lot# 12295: 4.04% Lot# 12299: 4.04%
(This value is used for neutralization planning only. This value is not intended to represent characterization values.)

Storage Conditions

- ☒ Room Temperature ☐ 2-8°C ☐ Other _____

Hazards

- ☐ None known: Use Standard Precautions
☒ Material Safety Data Sheet, Attached for each product
☐ As Follows: _____

Product Preparation

- ☐ No dilution required, Use as received (RTU)
☒ *Dilution(s) to be tested:

1:500 defined as 2oz + 1 gallon
(example: 1 oz/gallon) (amount of test substance) (amount of diluent)

- ☐ Deionized Water (Filter or Autoclave Sterilized)
☐ Tap Water (Filter or Autoclave Sterilized) - All tap water is softened; the water hardness for the batch of tap water used will be determined and reported.
☒ AOCG Synthetic Hard Water: 200 PPM
☐ Other _____

*Note: An equivalent dilution may be made unless otherwise requested by the Sponsor.

Test Virus: Infectious Laryngotracheitis virus

Exposure Time: 5 minutes

Exposure Temperature: ☒ Room temperature (to be based on regulatory agency of submission)
☐ Other: _____ °C (please specify range)

Directions for application of aerosol/spray products:

- ☐ Spray instructions are not applicable.

Trigger spray application:

- ☒ Spray carriers using 3 sprays, or until thoroughly wet, at a distance of 6 to 8 inches.
☐ Spray carriers using _____ sprays at a distance of _____ to _____ inches/cm. (circle one)

Aerosol spray application:

- ☐ Spray carriers for _____ seconds, or until thoroughly wet, at a distance of _____ to _____ inches/cm.


Organic Soil Load

- ☐ 1% lamb serum (minimum level that can be tested)
☒ 5% lamb serum
☐ Other _____

Template: 110-11

- Proprietary Information -

1285 Corporate Center Drive, Suite 110 • Eden, MN 55121 • 877.287.9378 • 851.378.5510 • www.viroxtechnologies.com



Protocol Number: VIR07052716.ILGT

Virox Technologies Inc.
Page 10 of 12



ACCURATUS
LAB SERVICES

Number of Carriers to be Tested

- ☒ One (typical for U.S. EPA submission)
☐ Five (required for broad-spectrum virucidal claims for Health Canada submission)

SPRAY BOTTLES USED IN TESTING (section only applicable for spray products)

To ensure expected levels of product are delivered, it is recommended that the Sponsor provide the spray bottles used in testing. Please indicate the desired source of the sprayer/bottles used in testing:

- ☒ Sprayer(s) and bottle(s) are provided by the Sponsor
☐ General purpose spray bottle(s) are to be provided by Accuratus Lab Services
☐ The spray nozzle(s) are provided by the Sponsor and general purpose bottle(s) will be provided by Accuratus Lab Services

REGULATORY AGENCY(IES) THAT MAY REVIEW DATA

- ☒ U.S. EPA
☐ Health Canada
☐ Therapeutic Goods Administration (Australian TGA)
☐ Not applicable - For internal/other use only (Efficacy result will be based on U.S. EPA requirements)

COMPLIANCE

Study to be performed under EPA Good Laboratory Practice regulations (40 CFR Part 160) and in accordance to standard operating procedures.

- ☒ Yes
☐ No (Non-GLP or Development Study)

PROTOCOL MODIFICATIONS

- ☒ Approved without modification
☐ Approved with modification

PROTOCOL ATTACHMENTS

Supplemental Information Form Attached - ☐ Yes ☒ No

TEST SUBSTANCE SHIPMENT STATUS

(This section is for informational purposes only.)

- ☐ Test Substance is already present at Accuratus Lab Services.
☒ Test Substance has been or will be shipped to Accuratus Lab Services.

Date of expected receipt at Accuratus Lab Services: _____

- ☐ Test Substance to be hand-delivered (must arrive by noon at least one day prior to testing or other arrangements made with the Study director).

Template: 110-1J

- Proprietary Information -

1285 Corporate Center Drive, Suite 110 • Eden, MN 55121 • 877.287.8378 • 651.379.5510 • www accuratuslabs.com



Protocol Number: VIR07052716.ILGT

Virox Technologies Inc.
Page 11 of 12



ACCURATUS
LAB SERVICES

TEST SUBSTANCE CHARACTERIZATION & STABILITY TESTING

[Verification required per 40 CFR Part 160 Subpart B (160.31(d))].

☐ Characterization/Stability testing is not required (For Non-GLP or Development testing only)

OR

Physical and Chemical Characterization (identity, purity, strength, activity, as applicable) of the test lots

☒ Physical & Chemical Characterization has been or will be completed prior to efficacy testing.

GLP compliance status of physical & chemical characterization testing:

☒ Testing was or will be performed following 40 CFR Part 160 GLP regulations

☐ Characterization has not been or will not be performed following GLP regulations

Check and complete the following that apply:

☒ A Certificate of Analysis (C of A) may be provided for each lot of test substance. If provided, the C of A will be appended to the report.

☐ Testing has been or will be conducted at Accuratus Lab Services under protocol or study #:

☐ Test has been or will be conducted by another facility under protocol or study #:

☐ Physical & Chemical Characterization was not or will not be performed prior to efficacy testing.

Stability Testing of the formulation

☒ Stability testing has been or will be completed prior to or concurrent with efficacy testing.

GLP compliance status of stability testing:

(GLP compliance is required by 40 CFR Part 160)

☒ Testing was or will be performed following 40 CFR Part 160 GLP regulations

☐ Stability testing has not been or will not be performed following GLP regulations

Check and complete the following that apply:


☐ Testing has been or will be conducted at Accuratus Lab Services under protocol or study #:

☒ Test has been or will be conducted by another facility under protocol or study #:

Study # 1021RA1

☐ Stability testing was not or will not be performed prior to or concurrent with efficacy testing.

If test substance characterization or stability testing information is not provided or is not performed following GLP regulations, this will be indicated in the GLP compliance statement of the final report.



Protocol Number: VIR07052716.ILGT

Virox Technologies Inc.
Page 12 of 12



ACCURATUS
LAB SERVICES

APPROVAL SIGNATURES

SPONSOR:

NAME: Mr. Babak Ghahchi TITLE: Senior Vice President of Quality Assurance and Regulatory Affairs

SIGNATURE: DATE: 06/10/16

PHONE: 1 (800) 813-0110 FAX: _____ EMAIL: babak@virox.com

For confidentiality purposes, study information will be released only to the sponsor representative signing the protocol (above) unless other individuals are specifically authorized in writing to receive study information.

Other individuals authorized to receive information regarding this study: ☐ See Attached

Lok Chum, Faraz Ahmedpour

Accuratus Lab Services:

NAME: Sharon Conway
Study Director

SIGNATURE: DATE: 10/30/16
Study Director

Template: 110-13

— Proprietary Information —

1296 Corporate Center Drive, Suite 110 • Eden, MN 55121 • 877.287.8378 • 651.379.5510 • www accuratuslabs.com